Skip to main content

Table 3 Multivariate analysis of factors associated with mortality among HIV-infected adults on antiretroviral therapy

From: Factors associated with 36-month loss to follow-up and mortality outcomes among HIV-infected adults on antiretroviral therapy in Central Kenya

 Multivariate Results (n = 23890)
6 months12 months24 months36 months
(n = 23890)aOR (95% CI)P valueaOR (95% CI)P valueaOR (95% CI)P valueaOR (95% CI)P value
Gender
 Male1.66 (1.38–2.00)< 0.0011.59 (1.35–1.87)< 0.0011.56 (1.35–1.80)< 0.0011.59 (1.39–1.83)< 0.001
 FemaleRef Ref Ref Ref 
Age groups
 20–35Ref Ref Ref Ref 
 36–501.06 (0.88–1.28)0.5451.15 (0.97–1.37)0.0981.10 (0.95–1.27)0.2231.09 (0.94–1.25)0.248
 51+1.34 (1.00–1.78)0.0471.54 (1.2–1.98)0.0011.52 (1.22–1.90)< 0.0011.51 (1.23–1.86)< 0.001
Marital Status
 Single1.30 (1.00–1.68)0.051.34 (1.07–1.68)0.011.36 (1.12–1.65)0.0021.36 (1.13–1.63)0.001
 Divorced1.99 (1.58–2.51)< 0.0011.86 (1.52–2.28)< 0.0011.80 (1.50–2.15)< 0.0011.86 (1.56–2.22)< 0.001
 MarriedRef Ref Ref Ref 
 Widowed1.33 (0.99–1.78)0.0551.14 (0.88–1.49)0.3301.23 (0.98–1.55)0.0711.26 (1.01–1.58)0.041
BMI
 < 18.51.65 (1.32–2.06)< 0.0011.57 (1.29–1.91)< 0.0011.55 (1.30–1.85)< 0.0011.54 (1.31–1.82)< 0.001
 18.5–24.9Ref Ref Ref Ref 
 25–29.90.58 (0.37–0.9)0.0150.62 (0.41–0.94)0.0230.65 (0.46–0.92)0.0140.68 (0.50–0.92)0.013
 30+0.41 (0.18–0.9)0.0260.49 (0.26–0.92)0.0270.57 (0.34–0.98)0.040.58 (0.36–0.94)0.027
CD4
 0–2502.66 (0.46–15.43)0.2752.51 (0.53–12.00)0.2491.59 (0.56–4.53)0.3881.68 (0.59–4.77)0.331
 251–5001.56 (0.26–9.47)0.6281.59 (0.33–7.76)0.5650.94 (0.32–2.78)0.9131.09 (0.37–3.18)0.873
 Above 500Ref Ref Ref Ref 
Regimen Started
 D4T-basedRef Ref Ref Ref 
 ABC-based0.95 (0.46–1.95)0.8890.71 (0.35–1.45)0.3460.60 (0.31–1.18)0.1400.52 (0.26–1.02)0.056
 AZT-based1.02 (0.81–1.28)0.8960.99 (0.80–1.21)0.8870.89 (0.74–1.07)0.2140.83 (0.70–0.99)0.04
 TDF-based0.58 (0.46–0.74)< 0.0010.57 (0.46–0.71)< 0.0010.57 (0.47–0.69)< 0.0010.55 (0.46–0.65)< 0.001
Baseline WHO Stage
 Stage IRef Ref Ref Ref 
 Stage II1.31 (0.86–2.01)0.2141.32 (0.90–1.95)0.1561.3 (0.93–1.83)0.1301.25 (0.91–1.72)0.167
 Stage III2.27 (1.49–3.47)< 0.0012.29 (1.56–3.35)< 0.0012.11 (1.53–2.91)< 0.0011.94 (1.43–2.63)< 0.001
 Stage IV5.29 (3.45–8.1)< 0.0015.10 (3.46–7.50)< 0.0014.79 (3.44–6.67)< 0.0014.24 (3.06–5.87)< 0.001